PHGE Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About PHGE Interactive Breakdown Better Bets vs. PHGE Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    BiomX (PHGE)

    Market Price (9/11/2026): $1.85 | Market Cap: $-Sector: Industrials | Industry: Aerospace & Defense

    BiomX (PHGE)

    Market Price (9/11/2026): $1.85
    Market Cap: $-
    Sector: Industrials
    Industry: Aerospace & Defense

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Weak multi-year price returns
    2Y Excs Rtn is -137%, 3Y Excs Rtn is -169%

    High stock price volatility
    Vol 12M is 203%

    Key risks
    PHGE key risks include [1] a critical cash shortage highlighted by a "going concern" qualification from its auditors, Show more.

    0 Weak multi-year price returns
    2Y Excs Rtn is -137%, 3Y Excs Rtn is -169%
    1 High stock price volatility
    Vol 12M is 203%
    2 Key risks
    PHGE key risks include [1] a critical cash shortage highlighted by a "going concern" qualification from its auditors, Show more.

    Valuation & Metrics

    null
    null
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Ulcer Size Reduction (Percentage Area Reduction - PAR) in Diabetic Foot Osteomyelitis (BX211)>40% reduction compared to placebo3312025Link
    Improvement in Ulcer Depth in Diabetic Foot Osteomyelitis (BX211)Statistically significant improvement (p=0.048)3312025Link
    Bacterial Load Reduction in Cystic Fibrosis (BX004)approximately 500-fold (2.7 log₁₀) reduction compared to placebo7082025Link
    Improvement in Pulmonary Function (FEV1) in Cystic Fibrosis (BX004)5.67% improvement compared to placebo in a predefined subgroup11292023Link
    Number of Employees5712312024Link
    Number of Clinical Programs in Pipeline311082025Link
    Number of Patent Documents (Applications and Grants)399042025Link

    Price Chart

    null
    null
    Recent
    8/19/2026Earnings ReleaseRev: $0.0 Mil (A) vs. $null (E)
    EPS: -0.37 (A) vs. $- (E)
    Upcoming
    9/09/2026Stock SplitRatio: 1-for-10

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 9/8/2026

    BiomX (PHGE) stock has lost about 85% since 5/31/2026 because of the following key factors:

    1. Strategic pivot and initial revenue generation in defense and security. BiomX successfully completed a strategic transition from its legacy biopharma focus to the defense, security, and critical infrastructure technology markets during the first half of fiscal year 2026. This pivot included discontinuing its BX004 clinical program and deconsolidating BiomX Israel in early 2026. The company reported its first recognized revenue of $0.33 million in fiscal Q2 2026, which ended June 30, 2026, marking a significant shift towards operational revenue in its new market.

    2. Key acquisitions and product deployments. In April 2026, BiomX acquired 100% of ZorroNet and a 60% controlling interest in DFSL, integrating their operations into its new defense and security focus. These acquisitions brought LADAR detection and AI command-and-control platforms into the company's portfolio. DFSL's LADAR and ZorroNet's AI platforms have since been deployed in pilot programs and operational sites, securing framework agreements, including one with Israel Railways.

    Show more
    Updated on 9/8/2026

    BiomX (PHGE) stock has lost about 85% since 5/31/2026 because of the following key factors:

    1. Strategic pivot and initial revenue generation in defense and security. BiomX successfully completed a strategic transition from its legacy biopharma focus to the defense, security, and critical infrastructure technology markets during the first half of fiscal year 2026. This pivot included discontinuing its BX004 clinical program and deconsolidating BiomX Israel in early 2026. The company reported its first recognized revenue of $0.33 million in fiscal Q2 2026, which ended June 30, 2026, marking a significant shift towards operational revenue in its new market.

    2. Key acquisitions and product deployments. In April 2026, BiomX acquired 100% of ZorroNet and a 60% controlling interest in DFSL, integrating their operations into its new defense and security focus. These acquisitions brought LADAR detection and AI command-and-control platforms into the company's portfolio. DFSL's LADAR and ZorroNet's AI platforms have since been deployed in pilot programs and operational sites, securing framework agreements, including one with Israel Railways.

    3. Positive fiscal Q2 2026 financial results. On August 19, 2026, BiomX reported its fiscal Q2 2026 results, announcing revenue of $0.33 million, a substantial improvement from $0.00 in the prior-year quarter. The company also reduced its net loss to $3.85 million in fiscal Q2 2026, compared to a net loss of $6.04 million in fiscal Q2 2025, driven by the new defense and security operations.

    4. Ongoing product development and commercial momentum. Recent news highlighted continued progress and commercial traction in the new defense segment. On September 4, 2026, BiomX's subsidiary ZorroNet launched a new no-code control feature for its AI-powered autonomous response workflows. Additionally, ZorroNet received an approximately $300,000 purchase order on August 14, 2026, to develop a unified operational environment at a defense technology test and evaluation site.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    null
    null

    Market Drivers

    5/31/2026 to 9/10/2026
    ReturnCorrelation
    PHGE-85.3% 
    Market (SPY)0.2%9.1%
    Sector (XLI)-1.5%-5.4%

    Fundamental Drivers

    null
    null

    Market Drivers

    2/28/2026 to 9/10/2026
    ReturnCorrelation
    PHGE-95.8% 
    Market (SPY)10.8%6.9%
    Sector (XLI)-3.4%10.7%

    Fundamental Drivers

    null
    null

    Market Drivers

    8/31/2025 to 9/10/2026
    ReturnCorrelation
    PHGE-98.2% 
    Market (SPY)18.5%10.5%
    Sector (XLI)13.4%12.6%

    Fundamental Drivers

    null
    null

    Market Drivers

    8/31/2023 to 9/10/2026
    ReturnCorrelation
    PHGE-99.8% 
    Market (SPY)74.2%6.9%
    Sector (XLI)64.1%7.4%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    PHGE Return-75%-88%50%-74%-87%-92%-100%
    Peers Return14%-60%11%-48%56%-3%-60%
    S&P 500 Return27%-19%24%23%16%12%103%

    Monthly Win Rates [3]
    PHGE Win Rate17%33%42%25%17%33% 
    Peers Win Rate40%33%43%37%58%53% 
    S&P 500 Win Rate75%42%67%75%67%44% 

    Max Drawdowns [4]
    PHGE Max Drawdown-83%-93%-58%-93%-92%-98% 
    Peers Max Drawdown-60%-72%-63%-66%-71%-52% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: ARMP, MCRB, NTLA, EDIT, BEAM.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 9/10/2026 (YTD)

    How Low Can It Go

    EventPHGES&P 500
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-35.5%-9.5%
      % Gain to Breakeven55.0%10.5%
      Time to Breakeven96 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-25.3%-6.7%
      % Gain to Breakeven33.9%7.1%
      Time to Breakeven29 days31 days

    Compare to ARMP, MCRB, NTLA, EDIT, BEAM

    In The Past

    BiomX's stock fell -35.5% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 55.0% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventPHGES&P 500
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-35.5%-9.5%
      % Gain to Breakeven55.0%10.5%
      Time to Breakeven96 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-25.3%-6.7%
      % Gain to Breakeven33.9%7.1%
      Time to Breakeven29 days31 days

    Compare to ARMP, MCRB, NTLA, EDIT, BEAM

    In The Past

    BiomX's stock fell -35.5% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 55.0% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About BiomX (PHGE)

    BiomX Inc. (PHGE) is a clinical-stage biotechnology company that specializes in developing innovative therapies using natural and engineered bacteriophages, often referred to as phages. Phages are a type of virus that specifically target and kill harmful bacteria without affecting human cells, offering a highly precise approach to treating various diseases. The company's core mission is to leverage this technology to address chronic conditions and diseases by eliminating specific problematic bacterial strains.

    BiomX's product pipeline is diversified, targeting several significant medical needs. Its most advanced product, BX004, is a phage therapy currently in Phase 1b/2a clinical trials for cystic fibrosis patients who suffer from chronic Pseudomonas aeruginosa respiratory infections. The company is also developing BX005, a topical phage cocktail in Phase 1/2 for Staphylococcus aureus bacteria, which is associated with skin conditions like atopic dermatitis. Additionally, BX003 is an orally administered phage cocktail in Phase 1b/2a, aimed at targeting specific gut bacteria implicated in inflammatory bowel diseases (IBD) and primary sclerosing cholangitis (PSC).

    Beyond these programs, BiomX is exploring a novel approach for colorectal cancer with a program utilizing engineered phages. These phages are designed to be administered intravenously to target Fusobacterium nucleatum bacteria, which are often found within tumor microenvironments. The company's overall market focus is on developing precision antibacterial therapies for patients suffering from chronic infections, inflammatory conditions, and certain cancers, addressing significant unmet medical needs in these areas.

    AI Analysis | Feedback

    BiomX is like Moderna, but instead of mRNA vaccines, they use viruses (phages) to precisely kill harmful bacteria.

    BiomX is like Crispr Therapeutics, but instead of editing human genes, they use viruses to precisely eliminate specific harmful bacteria.

    AI Analysis | Feedback

    • BX004: A phage therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa respiratory infections.
    • BX005: A topical phage cocktail targeting Staphylococcus aureus for atopic dermatitis.
    • BX003: An orally administered phage cocktail for inflammatory bowel diseases and primary sclerosing cholangitis.
    • Colorectal Cancer Program: An engineered phage therapy targeting Fusobacterium nucleatum bacteria within the tumor microenvironment for colorectal cancer.

    AI Analysis | Feedback

    BiomX Inc. (PHGE) is a clinical-stage microbiome company developing therapeutic products that are currently in various phases of clinical trials. As such, it does not yet have commercially approved products or major customers that purchase its therapies or services. Its products are investigational drugs targeting specific patient populations (e.g., CF patients, IBD and PSC patients, individuals with atopic dermatitis, or colorectal cancer patients), but these products are not yet available for sale.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Michael Oster, Chief Executive Officer

    Michael Oster brings over 25 years of experience in corporate finance, mergers and acquisitions (M&A), and complex international transactions, having held senior leadership roles in both public and private companies. He currently serves as Chief Executive Officer and a board member of Saffron Tech Ltd., an agritech company, and as a board member of BladeRanger Ltd., a publicly traded Israeli innovator in advanced drone payload systems. Earlier in his career, he was the Senior Vice President of Mergers and Acquisitions at Alon USA Energy, Inc., where he led numerous strategic transactions.

    David Rokach, Chief Financial Officer

    David Rokach possesses over two decades of experience in finance, investment management, and corporate leadership. He is responsible for BiomX’s financial strategy, capital markets activities, accounting, and investor relations. Since 2024, he has been a member of the board of directors of T3 Defense Inc. Previously, he held Chief Executive Officer positions at Newcom Finance and Granit Investment Company, and he has provided strategic and financial advisory services to corporations and hedge funds.

    AI Analysis | Feedback

    The key risks to BiomX (PHGE) are primarily centered around its financial viability and the success of its clinical development pipeline.

    1. Clinical Trial Failures and Regulatory Hurdles: A significant risk for BiomX stems from the inherent uncertainties of pharmaceutical research and development and the stringent regulatory approval process. In a major setback, BiomX announced the discontinuation of its Phase 2b clinical trial for nebulized phage therapy BX004, intended for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, in December 2025. This decision followed an internal analysis and recommendations from an independent Data Monitoring Committee due to unexpectedly high rates of adverse events. Prior to this, the U.S. portion of the BX004 Phase 2b study was already under an FDA clinical hold, albeit related to a third-party nebulizer and not the drug product itself, causing delays. The inability to successfully advance its primary drug candidates through clinical trials and obtain regulatory approval poses a critical threat to the company's future.
    2. Going Concern Risk and Insufficient Funding: BiomX faces substantial doubt about its ability to continue as a going concern due to severe liquidity pressure. As of September 30, 2025, the company reported a cash balance of $8.1 million, which was estimated to be sufficient to fund operations only into the first quarter of 2026. This necessitates securing additional financing or entering into partnerships, which could lead to significant shareholder dilution. The financial distress is so acute that in December 2025, BiomX initiated insolvency proceedings for its Israeli subsidiary, BiomX Ltd., which previously housed core operations and contributed to accumulated debts of approximately NIS 11 million (around $3.4 million).
    3. Lack of Revenue Generation: As a clinical-stage biotechnology company, BiomX has no approved products on the market and has not generated any revenue from product sales. The company operates at a net loss, with significant investment in research and development. This pre-revenue status means that BiomX is entirely reliant on external funding to advance its pipeline, making it highly vulnerable to the success of its clinical programs and its ability to raise capital.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    BiomX (PHGE) targets several significant addressable markets with its phage technology products:

    • BX004 for Cystic Fibrosis (CF) with Pseudomonas aeruginosa respiratory infections: The global cystic fibrosis therapeutics market was valued at $12.9 billion in 2024 and is projected to reach $32.3 billion by 2034. The global Pseudomonas aeruginosa treatment market was valued at $5.84 billion in 2024 and is projected to reach $11.81 billion by 2032. Specifically for BX004, the U.S. market in CF patients with chronic lung infections caused by Pseudomonas aeruginosa is estimated to be over $1 billion.
    • BX005 for Atopic Dermatitis targeting Staphylococcus aureus: The global atopic dermatitis drugs market was valued at approximately $12.1 billion in 2024 and is estimated to grow to $31 billion by 2034. Another source indicates the global atopic dermatitis treatment market was valued at $17.05 billion in 2024 and is expected to reach $32.04 billion by 2032.
    • BX003 for Inflammatory Bowel Diseases (IBD) and Primary Sclerosing Cholangitis (PSC): The global inflammatory bowel disease treatment market is expected to be valued at approximately $25.5 billion in 2025 and is estimated to reach $36.4 billion by 2032. The global primary sclerosing cholangitis (PSC) market size was valued at approximately $800 million in 2023 and is projected to grow to $1.2 billion by 2032.
    • Colorectal Cancer (CRC) program targeting Fusobacterium nucleatum: The global colorectal cancer therapeutics market size was valued at $12.79 billion in 2024 and is expected to reach approximately $19.95 billion by 2034.

    AI Analysis | Feedback

    BiomX Inc. (PHGE), a clinical-stage microbiome company, is not expected to generate significant commercial revenue within the immediate 2-3 year timeframe (2026-2028), as analysts currently forecast $0 revenue for 2026 and 2027, with some projections of approximately $11.2 million in 2028. Therefore, the primary drivers of future revenue growth for BiomX are centered on the successful advancement of its pipeline through clinical development and regulatory milestones, which would pave the way for eventual product commercialization. Here are the expected drivers of future revenue growth for BiomX over the next 2-3 years: * Advancement of Lead Clinical Programs Through Key Milestones: The successful progression of BiomX's lead product candidates, BX004 and BX011/BX211, through significant clinical trial readouts and positive regulatory interactions, is paramount for future revenue growth. This includes the anticipated topline results for the Phase 2b clinical trial of BX004, a phage therapy for cystic fibrosis patients with *Pseudomonas aeruginosa* respiratory infections, expected in Q1 2026. Additionally, leveraging the positive Phase 2 results for BX211 in diabetic foot osteomyelitis (DFO) and the clear clinical development path for BX011 in diabetic foot infections (DFI) will be crucial for moving these programs closer to market. Favorable feedback from regulatory bodies like the FDA, including supportive guidance for potential Phase 3 development, significantly de-risks these programs and enhances their commercial prospects. * Progression of Earlier-Stage Pipeline Candidates: Expanding and advancing other programs within the pipeline, such as BX003 for inflammatory bowel diseases (IBD) and primary sclerosing cholangitis (PSC), and the colorectal cancer program utilizing engineered phage, will contribute to the company's long-term revenue potential. Even if these programs do not reach commercialization within the next 2-3 years, their successful progression into later-stage clinical development or new indications would broaden BiomX's future market opportunities and increase its overall valuation. * Strategic Partnerships and Non-Dilutive Funding: As a pre-revenue, clinical-stage company, securing strategic collaborations with larger pharmaceutical entities and obtaining additional non-dilutive funding are vital for financing ongoing research and development (R&D) and clinical trials. Such partnerships can provide upfront payments, milestone payments upon achieving specific development or regulatory goals, and potential royalty agreements upon commercialization, thereby directly or indirectly supporting future revenue generation. The significant non-dilutive funding received from the U.S. Defense Health Agency for the BX211 program exemplifies this driver.

    AI Analysis | Feedback

    Share Issuance

    • In March 2026, BiomX shareholders approved the authorization to issue shares of Common Stock underlying Series Y convertible preferred stock and accompanying warrants, exceeding 19.99% of the existing Common Stock outstanding prior to the transaction.
    • In December 2025, the company finalized agreements for a private investment in public equity (PIPE) that would result in approximately $3.0 million in gross proceeds through the issuance of Series Y Convertible Preferred Stock and warrants.
    • In November 2025, BiomX implemented a one-for-nineteen reverse stock split, which reduced the number of outstanding shares from approximately 29 million to around 1.5 million.

    Inbound Investments

    • In December 2025, BiomX secured approximately $3 million through a private investment in public equity (PIPE) from certain investors.
    • In January 2026, Pyu Pyu Capital acquired a 19.99% stake in BiomX, as disclosed in a 13D filing.
    • In February 2025, the company raised $12 million in a financing round, which was led by Deerfield Management Company and included significant participation from the Cystic Fibrosis Foundation, along with contributions from Nantahala Capital and other investors.

    Capital Expenditures

    • For the last 12 months, BiomX's capital expenditures were reported as -$2,000, indicating minimal spending in this area.
    • As a clinical-stage biotechnology company, BiomX's investing cash flow is minimal, with its primary focus being on research and development rather than significant capital expenditures.

    Peer Outperformance in Aerospace & Defense

    PHGE has trailed 94% of its 54 Aerospace & Defense peers over 5Y. Aerospace & Defense ranks 4th of 23 industries in Industrials by median 5Y return.
    Share of Aerospace & Defense constituents that PHGE has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    0%
    of 70 industry peers · -97.9% return
    3Y
    3%
    of 60 industry peers · -99.7% return
    5Y
    6%
    of 54 industry peers · -100.0% return
    No Aerospace & Defense peer with a comparable growth profile has beaten PHGE by more than 20pp over 5Y.
    Median price return by industry across the Industrials sector, ranked by 5Y. Aerospace & Defense is PHGE's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Construction & Engineering 31 6.7%106.6%186.1% CDNL 2524% · FIX 2164% · STRL 2119%
    Marine Transportation 5 71.5%63.4%169.6% HOS 47268% · MATX 180% · KEX 170%
    Construction Machinery & Heavy Transportation Equipment 13 9.8%60.5%118.8% CAT 328% · ALSN 281% · WAB 223%
    Aerospace & Defense ← 55 -2.4%55.8%73.2% ATI 1049% · FTAI 890% · HWM 641%
    Passenger Ground Transportation 3 -20.8%32.6%54.0% UBER 82% · CAR 54% · LYFT -70%
    Rail Transportation 7 34.2%69.5%45.3% FSTR 140% · CSX 70% · UNP 54%
    Trading Companies & Distributors 19 2.8%34.1%38.5% DXPE 563% · AIT 286% · WCC 214%
    Industrial Machinery & Supplies & Components 71 4.4%44.2%35.8% CRS 1402% · PSIX 946% · GHM 595%
    Cargo Ground Transportation 16 39.9%3.6%34.1% XPO 256% · R 249% · CVLG 230%
    Diversified Support Services 33 9.3%25.8%27.6% LIME 3705% · TH 395% · WLFC 371%
    Electrical Components & Equipment 41 14.2%53.1%19.9% POWL 2198% · BE 1218% · VRT 916%
    Building Products 33 -11.6%-1.2%11.8% LMB 580% · GFF 397% · PPIH 297%
    Agricultural & Farm Machinery 17 14.7%-0.7%-6.3% BLBD 222% · DE 99% · GENC 58%
    Industrial Conglomerates 17 8.0%11.8%-6.6% RCMT 548% · CSW 130% · CSL 75%
    Environmental & Facilities Services 29 -11.4%23.5%-10.9% CECO 996% · ADUR 387% · NVRI 365%
    Research & Consulting Services 13 -10.0%-23.6%-11.5% HURN 204% · CRAI 92% · GRNQ 65%
    Data Processing & Outsourced Services 6 -32.6%-15.0%-26.0% EXLS 42% · BR 9% · G -26%
    Passenger Airlines 11 -0.4%-4.8%-28.5% LTM 3259% · UAL 140% · SKYW 121%
    Office Services & Supplies 9 8.3%26.9%-33.0% PBI 195% · TILE 142% · HNI 53%
    Human Resource & Employment Services 22 5.3%-22.2%-38.2% BBSI 82% · ADP 47% · PAYX 22%
    Security & Alarm Services 10 -33.0%5.7%-38.5% CIX 142% · MG 111% · NL 72%
    Air Freight & Logistics 12 -9.8%-25.0%-39.5% CHRW 94% · FDX 66% · EXPD 59%
    Airport Services 3 -69.9%-80.2%-58.7% JOBY -32% · ASLE -59% · UP -100%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    DOCNDigitalOcean13.725.0%172.3%
    ASOAcademy Sports and Outdoors3.524.3%9.2%
    SECZSecuritize1.223.5%-34.6%
    SEISolaris Energy Infrastructure3.821.6%40.1%
    WLTHWealthfront1.720.8%-19.9%
    APPSDigital Turbine1.420.7%136.0%
    ANGXAngel Studios1.019.8%15.2%
    ROIVRoivant Sciences29.519.8%88.7%
    COHUCohu2.619.6%135.2%
    SIGSignet Jewelers3.919.6%19.2%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    ADBTAdvasa0.2-82.0%-95.1%
    RAREUltragenyx Pharmaceutical1.5-45.7%-37.4%
    TTANServiceTitan5.3-39.2%-47.4%
    GWREGuidewire Software11.8-27.3%-30.3%
    DYNDyne Therapeutics3.0-26.7%-5.8%
    BRZEBraze2.7-26.3%-29.2%
    MEIMethode Electronics0.5-24.9%108.2%
    NAVNNavan5.1-24.7%18.6%
    TBBKBancorp2.1-24.3%-25.5%
    PATHUiPath7.3-22.9%-15.4%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    MRNAModerna54.4125.6%363.3%
    CAPRCapricor Therapeutics0.5111.2%-71.2%
    PURRHyperliquid Strategies1.467.6%209.3%
    ARXAccelerant4.358.5%21.3%
    AVAHAveanna Healthcare3.054.9%69.6%
    HTFLHeartFlow3.954.0%56.1%
    FWDIForward Industries0.650.9%-2.3%
    BTGOBitGo0.949.4%-59.9%
    WEAVWeave Communications0.645.1%-3.8%
    CVICVR Energy4.942.7%92.2%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    ALMSAlumis1.3-61.0%1.4%
    IESCIES12.7-47.9%-17.9%
    RAREUltragenyx Pharmaceutical1.5-46.6%-37.4%
    KRMNKarman4.6-44.5%-53.0%
    AADXApplied Aerospace & Defense1.7-44.0%-39.3%
    AEVAAeva Technologies1.0-37.8%12.7%
    LCIDLucid1.6-37.6%-60.5%
    TTANServiceTitan5.3-36.6%-47.4%
    DKSDick's Sporting Goods11.7-35.7%-32.6%
    CRDOCredo Technology29.6-35.3%11.4%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    PHGEARMPMCRBNTLAEDITBEAMMedian
    NameBiomX Armata P.Seres Th.Intellia.Editas M.Beam The. 
    Mkt Price1.855.235.1011.932.6524.375.17
    Mkt Cap-0.20.01.60.32.50.3
    Rev LTM-02604715647
    Op Inc LTM--35-78-423-83-378-83
    FCF LTM--26-51-349-121-373-121
    FCF 3Y Avg--35-99-384-166-294-166
    CFO LTM--25-51-347-120-359-120
    CFO 3Y Avg--32-98-380-162-281-162

    Growth & Margins

    PHGEARMPMCRBNTLAEDITBEAMMedian
    NameBiomX Armata P.Seres Th.Intellia.Editas M.Beam The. 
    Rev Chg LTM---12.6%20.8%158.9%20.8%
    Rev Chg 3Y Avg---4.7%75.3%138.6%75.3%
    Rev Chg Q----46.2%232.3%-94.2%-46.2%
    QoQ Delta Rev Chg LTM--64.2%-10.0%21.5%-4.9%8.3%
    Op Inc Chg LTM-0.1%29.0%17.3%48.1%15.2%17.3%
    Op Inc Chg 3Y Avg-3.6%-8.0%1.9%24.7%-25.0%1.9%
    Op Mgn LTM---4,154.4%-711.7%-177.6%-242.3%-477.0%
    Op Mgn 3Y Avg----940.1%-302.9%-344.8%-344.8%
    QoQ Delta Op Mgn LTM--3,486.6%-75.1%52.5%-15.7%18.4%
    CFO/Rev LTM---2,722.1%-582.5%-255.0%-230.3%-418.8%
    CFO/Rev 3Y Avg----728.8%-339.4%-280.5%-339.4%
    FCF/Rev LTM---2,724.1%-586.0%-256.5%-238.9%-421.2%
    FCF/Rev 3Y Avg----738.8%-346.4%-290.8%-346.4%

    Valuation

    PHGEARMPMCRBNTLAEDITBEAMMedian
    NameBiomX Armata P.Seres Th.Intellia.Editas M.Beam The. 
    Mkt Cap-0.20.01.60.32.50.3
    P/S--26.326.86.716.321.3
    P/Op Inc--5.4-0.6-3.8-3.8-6.7-3.8
    P/EBIT--1.12.3-3.8-4.5-6.7-3.8
    P/E--1.0-2.2-4.0-4.3-29.8-4.0
    P/CFO--7.6-1.0-4.6-2.6-7.1-4.6
    Total Yield--100.0%-45.4%-25.1%-23.4%-3.4%-25.1%
    Dividend Yield-0.0%0.0%0.0%0.0%0.0%0.0%
    FCF Yield 3Y Avg--34.7%-1,165.5%-25.5%-62.1%-13.0%-34.7%
    D/E-1.61.10.00.00.10.1
    Net D/E-1.50.8-0.2-0.6-0.4-0.2

    Returns

    PHGEARMPMCRBNTLAEDITBEAMMedian
    NameBiomX Armata P.Seres Th.Intellia.Editas M.Beam The. 
    1M Rtn16.5%23.1%9.9%-0.7%-10.2%-9.2%4.6%
    3M Rtn-73.9%-30.0%-19.3%-3.4%8.6%-17.1%-18.2%
    6M Rtn-97.1%-50.8%-43.6%-7.2%4.3%-4.8%-25.4%
    12M Rtn-97.9%75.5%-71.0%5.7%3.5%22.6%4.6%
    3Y Rtn-99.7%72.0%-91.7%-68.8%-71.1%-6.6%-70.0%
    1M Excs Rtn18.3%24.8%11.7%1.0%-8.4%-7.5%6.3%
    3M Excs Rtn-75.6%-35.3%-25.9%-6.7%2.4%-21.8%-23.9%
    6M Excs Rtn-109.1%-66.6%-54.9%-20.3%-12.4%-18.6%-37.6%
    12M Excs Rtn-114.6%60.8%-89.2%-16.1%-20.6%3.1%-18.4%
    3Y Excs Rtn-168.6%-5.4%-161.6%-137.4%-138.8%-65.9%-138.1%

    Comparison Analyses

    null

    Segment Financials

    Operating Income by Segment
    $ Mil20252024
    Clinical stage product discovery company developing products using both natural and engineered-41-45
    Total-41-45


    Assets by Segment
    $ Mil20242023202220212020
    Clinical stage product discovery company developing products using both natural and engineered4325467870
    Total4325467870


    Price Behavior

    Price Behavior
    Market Price$1.85 
    Market Cap ($ Bil)0.0 
    First Trading Date03/13/2019 
    Distance from 52W High-98.5% 
       50 Days200 Days
    DMA Price$1.89$22.90
    DMA Trenddowndown
    Distance from DMA-2.1%-91.9%
     3M1YR
    Volatility99.2%203.6%
    Downside Capture300.72630.47
    Upside Capture-404.2368.34
    Correlation (SPY)1.6%11.1%
    PHGE Betas & Captures as of 8/31/2026

     1M2M3M6M1Y3Y
    Beta1.820.941.151.3712.403.34
    Up Beta1.082.824.280.0217.242.59
    Down Beta-4.82-1.780.23-2.98-0.770.31
    Up Capture24%-206%-278%-80%2013%205%
    Bmk +ve Days10213268138427
    Stock +ve Days813183792308
    Down Capture731%421%382%305%203%113%
    Bmk -ve Days11213259113324
    Stock -ve Days13274386155426

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with PHGE
    PHGE-98.4%202.6%-1.18-
    Sector ETF (XLI)14.8%17.2%0.6313.2%
    Equity (SPY)17.6%12.8%0.9911.3%
    Gold (GLD)18.7%29.2%0.5910.3%
    Commodities (DBC)47.9%20.4%1.81-2.8%
    Real Estate (VNQ)6.6%13.6%0.228.1%
    Bitcoin (BTCUSD)-29.9%43.8%-0.688.5%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with PHGE
    PHGE-81.7%161.8%-0.44-
    Sector ETF (XLI)12.0%17.6%0.528.2%
    Equity (SPY)12.4%17.2%0.556.9%
    Gold (GLD)18.5%18.8%0.807.9%
    Commodities (DBC)11.5%19.5%0.461.3%
    Real Estate (VNQ)0.7%18.9%-0.074.3%
    Bitcoin (BTCUSD)9.9%52.6%0.376.2%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with PHGE
    PHGE-60.9%138.1%-0.38-
    Sector ETF (XLI)13.1%20.1%0.577.6%
    Equity (SPY)15.1%17.9%0.717.0%
    Gold (GLD)12.2%16.3%0.617.1%
    Commodities (DBC)8.4%18.1%0.382.5%
    Real Estate (VNQ)4.6%20.7%0.194.9%
    Bitcoin (BTCUSD)63.4%66.2%1.036.6%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date8142026
    Short Interest: Shares Quantity0.3 Mil
    Short Interest: % Change Since 7312026-29.4%
    Average Daily Volume1.9 Mil
    Days-to-Cover Short Interest1

    Earnings Returns History

    Updated 9/9/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    11/12/2025-1.9%-26.3%-68.7%
    8/13/2025-11.7%-2.5%-9.4%
    5/15/20253.1%-2.9%-25.2%
    3/25/2025-7.2%-11.8%-6.2%
    11/14/20243.6%-29.7%-12.4%
    4/3/2024-8.9%-8.6%15.7%
    11/14/2023-1.2%-5.2%-25.0%
    8/9/2023-9.3%-10.2%-7.1%
    ...
    SUMMARY STATS   
    # Positive513
    # Negative131715
    Median Positive3.1%0.3%15.7%
    Median Negative-6.1%-10.2%-18.7%
    Max Positive7.2%0.3%25.4%
    Max Negative-11.7%-29.7%-68.7%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    11/12/2025-1.9%-26.3%-68.7%
    8/13/2025-11.7%-2.5%-9.4%
    5/15/20253.1%-2.9%-25.2%
    3/25/2025-7.2%-11.8%-6.2%
    11/14/20243.6%-29.7%-12.4%
    4/3/2024-8.9%-8.6%15.7%
    11/14/2023-1.2%-5.2%-25.0%
    8/9/2023-9.3%-10.2%-7.1%
    5/15/20237.2%0.3%25.4%
    3/29/20232.2%-11.8%-10.4%
    11/9/2022-4.4%-23.5%-33.8%
    8/10/2022-6.4%-7.5%-31.6%
    5/11/2022-6.1%-13.9%-31.1%
    11/15/2021-4.8%-20.1%-33.7%
    8/16/2021-7.7%-6.4%-18.7%
    5/24/20211.6%-1.0%-10.6%
    3/31/2021-1.5%-12.3%-5.0%
    11/12/2020-0.2%-1.2%5.9%
    SUMMARY STATS   
    # Positive513
    # Negative131715
    Median Positive3.1%0.3%15.7%
    Median Negative-6.1%-10.2%-18.7%
    Max Positive7.2%0.3%25.4%
    Max Negative-11.7%-29.7%-68.7%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/19/202610-Q
    03/31/202605/20/202610-Q
    12/31/202502/19/202610-K
    09/30/202511/12/202510-Q
    06/30/202508/13/202510-Q
    03/31/202505/15/202510-Q
    12/31/202403/25/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/14/202410-Q
    03/31/202405/20/202410-Q
    12/31/202304/04/202410-K
    09/30/202311/14/202310-Q
    06/30/202308/09/202310-Q
    03/31/202305/15/202310-Q
    12/31/202203/29/202310-K
    09/30/202211/09/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/19/202610-Q
    03/31/202605/20/202610-Q
    12/31/202502/19/202610-K
    09/30/202511/12/202510-Q
    06/30/202508/13/202510-Q
    03/31/202505/15/202510-Q
    12/31/202403/25/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/14/202410-Q
    03/31/202405/20/202410-Q
    12/31/202304/04/202410-K
    09/30/202311/14/202310-Q
    06/30/202308/09/202310-Q
    03/31/202305/15/202310-Q
    12/31/202203/29/202310-K
    09/30/202211/09/202210-Q
    06/30/202208/10/202210-Q
    03/31/202205/11/202210-Q
    12/31/202103/30/202210-K
    09/30/202111/15/202110-Q
    06/30/202108/16/202110-Q
    03/31/202105/24/202110-Q
    12/31/202003/31/202110-K
    09/30/202011/12/202010-Q
    06/30/202008/13/202010-Q
    03/31/202005/14/202010-Q
    12/31/201903/26/202010-K
    09/30/201910/16/201910-Q

    Insider Activity

    Updated 4/26/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Yeganeh, ReuvenPyu Pyu Capital LLCSell31820265.00530,000  Form
    2Yeganeh, ReuvenPyu Pyu Capital LLCSell31820265.00450,000  Form
    3Yeganeh, ReuvenPyu Pyu Capital LLCSell31320265.00370,000  Form
    4Yeganeh, ReuvenPyu Pyu Capital LLCSell31320265.00300,000  Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Yeganeh, ReuvenPyu Pyu Capital LLCSell31820265.00530,000  Form
    2Yeganeh, ReuvenPyu Pyu Capital LLCSell31820265.00450,000  Form
    3Yeganeh, ReuvenPyu Pyu Capital LLCSell31320265.00370,000  Form
    4Yeganeh, ReuvenPyu Pyu Capital LLCSell31320265.00300,000  Form

    Industry Resources

    Industrials Resources
    IndustryWeek
    Manufacturing.net
    Aviation Week
    Aerospace & Defense Resources
    Defense News
    FlightGlobal

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 9/10/2026